# Evgen Pharma Plc Final Results for the year ended 31 March 2018

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-final-results-year-ended-31-march-2018/412752755
- Published: 2018-06-13T07:13:52+01:00
- Author: Giles Arbor

Evgen Pharma plc (LON:EVG), the clinical stage drug development company focused 
on the treatment of cancer and neurological conditions, announces its final results
for the year ended 31 March 2018.

Highlights

* Interim data released from ongoing STEM (SFX-01 in the Treatment and Evaluation
of Metastatic Breast Cancer) Phase IIa clinical study

* 11 new sites opened for STEM trial in Spain, France, Belgium and UK and a total
of 44 patients recruited to date

* 2 new sites opened in UK in ongoing SAS (SFX-01 After Subarachnoid Haemorrhage)
Phase IIb clinical study and 65 patients recruited to date

* Launch of Scientific and Medical Advisory Board (“SMAB”) with, as initial members,
the sulforaphane experts Professor Giovanni Mann, Professor of Vascular Physiology,
King’s College, London, and Professor Albena Dinkova-Kostova, Professor of Chemical
Biology, University of Dundee

* Further elucidation of SFX-01 mechanism of action in breast cancer

* Additional patents granted over SFX-01 including first patent grant in Europe 
for SFX-01, relating to manufacturing and scale-up processes

* Financial performance in line with expectations:

– Total comprehensive loss of £2.6m (2017: loss of £3.1m)

– Net cash outflow of £0.2m (2017: outflow of £3.3m (before short-term investment
movements))

– Cash and short-term investments and cash on deposit at 31 March 2018 of £3.63m(
31 March 2017: £3.86m)

* Fundraising in December 2017 raised £2.1m after expenses

> **Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma Plc, said:**  “
> We are very encouraged by the interim data from the STEM trial which was announced
> earlier this week. Patient recruitment in both trials is on track to report around
> the end of the year.
> “Interest in the potential of sulforaphane continues to gain momentum. There are
> now approximately 1,800 peer-reviewed scientific publications on sulforaphane 
> and, since the beginning of 2018, the publication rate is running at an all-time
> high of over five publications per week.
> “With the ongoing growth of scientific data supporting the therapeutic potential
> of sulforaphane, together with the positive progress of our Phase II trials, we
> remain confident in the prospects for the Company.”

Share on:
